Table 1.
Baseline Characteristics of Included COVID-19 Cases (March 16–May 31, 2022)
| Characteristic | Bebtelovimab | No Bebtelovimab | P |
|---|---|---|---|
| No. | 377 | 377 | |
| Age group, No. (%) | .937 | ||
| 18–49 y | 23 (6.1) | 23 (6.1) | |
| 50–64 y | 79 (21.0) | 72 (19.1) | |
| 65–79 y | 185 (49.1) | 189 (50.1) | |
| ≥80 y | 90 (23.9) | 93 (24.7) | |
| Male sex, No. (%) | 180 (47.7) | 170 (45.1) | .511 |
| Race and ethnicity, No. (%) | .404 | ||
| Asian | 6 (1.6) | 6 (1.6) | |
| Black | 9 (2.4) | 13 (3.4) | |
| Hispanic or Latinx | 14 (3.7) | 10 (2.7) | |
| Other or unavailable | 10 (2.7) | 4 (1.1) | |
| White | 338 (89.7) | 344 (91.2) | |
| High SES vulnerability of zip code, No. (%) | 34 (9.0) | 30 (8.0) | .695 |
| Vaccination status, No. (%) | .971 | ||
| Vaccinated and boosted | 310 (82.2) | 306 (81.2) | |
| Vaccinated | 47 (12.5) | 49 (13.0) | |
| Partially vaccinated | 3 (0.8) | 4 (1.1) | |
| Unvaccinated | 17 (4.5) | 18 (4.8) | |
| Last vaccine dose >20 weeks prior, No. (%) | 287 (76.1) | 300 (79.6) | .293 |
| Comorbidity score, MASS, median (IQR) | 8 [6–11] | 8 [6–11] | .802 |
| Age, median (IQR) | 71 [64–79] | 71 [64–79] | .694 |
| Solid organ transplant, No. (%) | 68 (18.0) | 66 (17.5) | .924 |
| Stem cell transplant, No. (%) | 8 (2.1) | 11 (2.9) | .642 |
| BMI, No. (%) | .496 | ||
| <25 kg/m2 or unavailable | 100 (26.5) | 111 (29.4) | |
| 25–30 kg/m2 | 129 (34.2) | 112 (29.7) | |
| 30–35 kg/m2 | 80 (21.2) | 77 (20.4) | |
| >35 kg/m2 | 68 (18.0) | 77 (20.4) | |
| Immunocompromise, No. (%) | 298 (79.0) | 304 (80.6) | .650 |
| Diabetes, No. (%) | 150 (39.8) | 156 (41.4) | .711 |
| Heart disease or stroke, No. (%) | 207 (54.9) | 169 (44.8) | .007 |
| Pulmonary disease, No. (%) | 89 (23.6) | 97 (25.7) | .554 |
| Bipolar, schizophrenia, and other disorders, No. (%) | 23 (6.1) | 17 (4.5) | .417 |
| Depression and anxiety, No. (%) | 120 (31.8) | 100 (26.5) | .128 |
| Hematologic malignancy, No. (%) | 38 (10.1) | 34 (9.0) | .710 |
| Solid tumor malignancy, No. (%) | 214 (56.8) | 226 (59.9) | .416 |
| Rheumatologic or inflammatory bowel disease, No. (%) | 70 (18.6) | 50 (13.3) | .059 |
Immunocompromise includes patients with history of malignancy and patients on immunosuppressive medications.
Abbreviations: BMI, body mass index; COVID-19, coronavirus disease 2019; MASS, Monoclonal Antibody Screening Score; SES, socioeconomic status.